Oncology research and drug discovery by Cullinan Therapeutics
Cullinan Therapeutics shares Genrix Phase 1b 2a velinotamig clinical data in SLE
Cullinan Therapeutics has released clinical data from its ongoing Genrix Phase 1b 2a study evaluating velinotamig, a BCMAxCD3 T cell engager, for systemic lupus erythematosus (SLE). The newly ...
Cullinan Therapeutics to present CLN-049 and velinotamig investigational data at ASH26
Cullinan Therapeutics announced that its investigational FLT3xCD3 T cell engager CLN-049 and BCMAxCD3 T cell engager velinotamig will be featured across four poster presentations at the ASH26 ...
Cullinan Therapeutics receives clearance for global Phase 1 2 study of velinotamig
Cullinan Therapeutics announced that the U.S. FDA and Australian TGA have granted clearance to initiate a global Phase 1 2 clinical study of velinotamig. The study will evaluate this BCMAxCD3 T ...
Zipalertinib demonstrates clinical benefit in EGFR ex20ins NSCLC, Cullinan Therapeutics reports
Cullinan Therapeutics announced new clinical data showing that zipalertinib achieved clinically meaningful intracranial antitumor activity in patients with EGFR exon 20 insertion or uncommon ...
Cullinan Therapeutics doses first patient in registrational Phase 2 CLN-049 study for acute myeloid leukemia
Cullinan Therapeutics has begun dosing patients in its planned registrational Phase 2 study evaluating CLN-049, an investigational FLT3 T cell engager, in adults with relapsed or refractory acute ...
Cullinan Therapeutics submits NDA for lung cancer therapy in partnership with Taiho
Cullinan Therapeutics announced the initiation of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational drug zipalertinib in combination with ...
Cullinan Therapeutics outlines fourth quarter 2026 milestones in T cell engager pipeline
Cullinan Therapeutics has announced its planned milestones for the fourth quarter of 2026 across its immunology and oncology T cell engager portfolio. The update includes anticipated clinical ...
Cullinan Therapeutics to present Phase 3 trial results at WCLC26
Cullinan Therapeutics, in collaboration with Taiho Oncology and Taiho Pharmaceutical, has announced first-line Phase 3 REZILIENT3 trial data at the World Conference on Lung Cancer 2026 (WCLC26). ...
Cullinan Therapeutics to present interim Phase 3 REZILIENT3 trial results at WCLC26
Cullinan Therapeutics announced it will present interim results from its Phase 3 REZILIENT3 trial at the International Association for the Study of Lung Cancer’s WCLC26 conference. The study ...
Cullinan Therapeutics announces webcast for REZILIENT3 Phase 3 study results on zipalertinib
Cullinan Therapeutics will host a virtual analyst and investor webcast on September 14 to present new data from its Phase 3 REZILIENT3 trial evaluating zipalertinib combined with chemotherapy. The ...
Cullinan Therapeutics joins ITP Conference 2026 to deepen ties with patient and physician community
Cullinan Therapeutics participated in the ITP Conference 2026 organized by @PDSA_ITP, aiming to engage with patients and physicians involved in immune thrombocytopenia (ITP). The event offered an ...
Cullinan Therapeutics targets rheumatoid arthritis with CD19 T cell engager
Cullinan Therapeutics is progressing the development of its CD19-directed T cell engager, CLN-978, as a potential treatment for autoimmune diseases including rheumatoid arthritis, Sjögren’s ...
Cullinan Therapeutics posts Q2 2026 financial results and updates on T cell engager pipeline milestones
Cullinan Therapeutics reported its corporate update and financial results for the second quarter of 2026, sharing details on business performance and developments in its T cell engager pipeline. ...
OUTbio Boston event draws LGBTQIA biotech talent with Cullinan Therapeutics sponsorship
Cullinan Therapeutics supported the LGBTQIA biotechnology community by sponsoring the recent OUTbio Boston Networking Event through its PRISM initiative. The gathering brought together LGBTQIA ...
Cullinan Therapeutics advances CLN-049 to Phase 2 after positive FDA feedback
Cullinan Therapeutics announced it has received positive feedback from the U.S. Food and Drug Administration following an End-of-Phase 1 meeting for its investigational therapy CLN-049. The ...
Cullinan Therapeutics senior leaders use personal experience to inspire clinical development
Jerry Walis, Senior Director of GxP Quality Systems at Cullinan Therapeutics, shares how living with multiple autoimmune diseases motivates him to make a difference for others. He joined Antoine ...
Cullinan Therapeutics CSO to join MITCEO Conference panel on advancing patient medicines
Cullinan Therapeutics announced that Chief Scientific Officer Jennifer Michaelson, PhD, will participate in a discussion at the Longwood Healthcare Leaders MITCEO Conference next Tuesday. The ...
Cullinan Therapeutics details new biomarker approach for immune reset in autoimmune disease research
Cullinan Therapeutics has introduced a new biomarker-driven approach aimed at elucidating immune reset mechanisms in autoimmune diseases, according to a MassBio article. Chief Scientific Officer ...
Cullinan Therapeutics presents initial clinical data for CLN-978 in refractory SLE and RA
Cullinan Therapeutics has unveiled initial clinical data for CLN-978, an investigational CD19xCD3 T cell engager, targeting patients with refractory systemic lupus erythematosus (SLE) and ...
Cullinan Therapeutics explores B cell depletion in novel autoimmune treatments
Cullinan Therapeutics is exploring innovative T cell engager therapies aimed at depleting disease-causing B cells, presenting a new approach to treating autoimmune diseases by addressing their ...
Cullinan Therapeutics to unveil initial clinical data on CD19 and BCMA T cell engagers
Cullinan Therapeutics is set to host an Immunology Day for investors and analysts on June 10 to present initial clinical data from its CD19- and BCMA-targeted T cell engager therapies for ...
